Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants - Wikidata - awgldk - TriplyDB

Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants

Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants

http://www.wikidata.org/entity/Q34302085

about

A Blueprint for HIV Vaccine Discovery Structure-based stabilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding site Thermostability of Well-Ordered HIV Spikes Correlates with the Elicitation of Autologous Tier 2 Neutralizing Antibodies Viremic HIV infected individuals with high CD4 T cells and functional envelope proteins show anti-gp41 antibodies with unique specificity and function Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data.Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1).Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion.Inhibition of HIV-1 endocytosis allows lipid mixing at the plasma membrane, but not complete fusion.A monoclonal Fab derived from a human nonimmune phage library reveals a new epitope on gp41 and neutralizes diverse human immunodeficiency virus type 1 strains.Sequestering of the prehairpin intermediate of gp41 by peptide N36Mut(e,g) potentiates the human immunodeficiency virus type 1 neutralizing activity of monoclonal antibodies directed against the N-terminal helical repeat of gp41 B cell recognition of the conserved HIV-1 co-receptor binding site is altered by endogenous primate CD4.Anti-HIV-1 response elicited in rabbits by anti-idiotype monoclonal antibodies mimicking the CD4-binding site Affinity maturation by targeted diversification of the CDR-H2 loop of a monoclonal Fab derived from a synthetic naïve human antibody library and directed against the internal trimeric coiled-coil of gp41 yields a set of Fabs with improved HIV-1 neut Early steps of HIV-1 fusion define the sensitivity to inhibitory peptides that block 6-helix bundle formation.Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection.SERINC5 protein inhibits HIV-1 fusion pore formation by promoting functional inactivation of envelope glycoproteins.Protease cleavage sites in HIV-1 gp120 recognized by antigen processing enzymes are conserved and located at receptor binding sites Comparative immunogenicity of subtype a Human Immunodeficiency Virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopes Multi-Parameter Exploration of HIV-1 Virus-Like Particles as Neutralizing Antibody Immunogens in Guinea Pigs, Rabbits and Macaques Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs HIV infection of macrophages is enhanced in the presence of increased expression of CD163 induced by substance P Binding of HIV-1 gp41-directed neutralizing and non-neutralizing fragment antibody binding domain (Fab) and single chain variable fragment (ScFv) antibodies to the ectodomain of gp41 in the pre-hairpin and six-helix bundle conformations A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals.PD 404,182 is a virocidal small molecule that disrupts hepatitis C virus and human immunodeficiency virus.Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates.Immunization with wild-type or CD4-binding-defective HIV-1 Env trimers reduces viremia equivalently following heterologous challenge with simian-human immunodeficiency virus.Specificity of the autologous neutralizing antibody response Mucosal and systemic anti-HIV immunity controlled by A20 in mouse dendritic cells Neutralizing antibody responses in macaques induced by human immunodeficiency virus type 1 monovalent or trivalent envelope glycoproteins.Comparison of neutralizing antibody responses elicited from highly diverse polyvalent heterotrimeric HIV-1 gp140 cocktail immunogens versus a monovalent counterpart in rhesus macaques Dense display of HIV-1 envelope spikes on the lambda phage scaffold does not result in the generation of improved antibody responses to HIV-1 Env.Mirabamides E-H, HIV-inhibitory depsipeptides from the sponge Stelletta clavosa Sub-inhibitory concentrations of human α-defensin potentiate neutralizing antibodies against HIV-1 gp41 pre-hairpin intermediates in the presence of serum.Selected HIV-1 Env trimeric formulations act as potent immunogens in a rabbit vaccination model.Structure-based vaccine design in HIV: blind men and the elephant?Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterolo Highly potent chimeric inhibitors targeting two steps of HIV cell entry Neutralizing and other antiviral antibodies in HIV-1 infection and vaccination.Synergistic inhibition of HIV-1 envelope-mediated membrane fusion by inhibitors targeting the N and C-terminal heptad repeats of gp41.Rapid development of glycan-specific, broad, and potent anti-HIV-1 gp120 neutralizing antibodies in an R5 SIV/HIV chimeric virus infected macaque

P2860

Q26829865-CBD5817E-EFDA-4FE2-942B-75BDA536C5CF Q27316899-5AC18A04-AFF7-4B9D-87A9-96E3122549F0 Q28553360-EC5E0109-7B3B-4462-885E-85ADB58341ED Q28732293-8B89315C-E260-46D3-BE94-D79AF24613A7 Q30378421-3BE9C849-99E7-4890-94E1-3A55F56F5A39 Q30379200-E421672A-1531-4252-B4FB-0D4C99378F16 Q30413695-62D81A84-7335-4F6F-BBF4-9B4FB8689897 Q30507959-F7807D9F-5BE3-4970-AA59-D13C593FF031 Q33300529-4DD0ED35-AC82-46F4-8DEF-EA2D48E948AA Q33356323-1E95D880-09D2-4F9F-9C73-C0449F96B8E9 Q33373664-8839B6B3-EF74-476E-8F84-85D1CBC0C198 Q33377024-005DA26F-4CC2-406D-A8A8-9A52DC0A889C Q33495440-31015ABE-0182-4397-9496-AD852ECD6053 Q33504556-38112E81-97DE-4996-A263-227DC5204499 Q33504604-B2195B84-66A3-42F8-84AF-633B8FA95390 Q33567639-76FC2C11-8772-4FF0-9DF8-B29D101202A9 Q33614461-1FBDCE02-62B0-4137-9386-32AA0FAEAAFA Q33648910-1871322D-EECE-4659-BFEA-65AE44E70AF7 Q33683203-A60C77A9-B4CB-4A0B-8349-4413111E23C0 Q33725679-82C07DD1-0F96-4FDD-89F9-015370CE9329 Q33750864-C14F78D3-5E1C-4F4C-881B-0634A23F25AC Q34020570-6468735E-9653-4768-8401-9DEEB297E94F Q34047445-CF2C2D68-76FD-4BB9-AE61-CE01BBDDB6E1 Q34074331-6C9E793F-1E2A-4AD0-9BE6-DCE944D390F9 Q34096530-DCF5EE24-C780-4FF9-AFD8-DEC88CD7D429 Q34120088-4E928961-D89B-447C-A946-39B1C6F62B3E Q34415389-3E074CE3-C86D-4326-B278-9EC60F803731 Q34519838-49B4270F-9DBD-43D8-B4B4-3D5AFD3B45AD Q34637968-3EF75876-B40A-4D3E-A623-4545F6AA80A0 Q34663118-CE15D8C3-0701-4B3F-93C2-AFCFC5965A71 Q34706815-30C85FC4-502C-4121-AF82-0997B69EA99A Q34769803-AFDC5804-491A-4B83-A5EF-7BFB308CDED6 Q34778515-D70641E3-788D-41AD-86D4-F4ACD261EC0F Q34984724-35C40941-37D4-42CA-A20B-231EFF7EC265 Q34987048-9950FF04-D776-4CF9-B920-44F5D307A322 Q35024202-5E0E07F4-A4E2-4895-8DF6-0EE1BE833BA7 Q35150195-374EF98E-21A9-4BE7-B5B5-31924014C9E4 Q35208657-A04FB9FE-41A6-497D-B067-A4970C7C2BBC Q35616634-5481F147-8B53-4B6B-BDDA-80E41913E507 Q35647701-3F8F8B46-AB33-43C7-87C2-FD2F02C58AB0

P2860

Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants

http://www.wikidata.org/entity/Q34302085

description

2006 nî lūn-bûn

@nan

2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Characterization of antibody r ...... proteins in selected adjuvants

@ast

Characterization of antibody r ...... proteins in selected adjuvants

@en

Characterization of antibody r ...... proteins in selected adjuvants

@nl

type

label

Characterization of antibody r ...... proteins in selected adjuvants

@ast

Characterization of antibody r ...... proteins in selected adjuvants

@en

Characterization of antibody r ...... proteins in selected adjuvants

@nl

prefLabel

Characterization of antibody r ...... proteins in selected adjuvants

@ast

Characterization of antibody r ...... proteins in selected adjuvants

@en

Characterization of antibody r ...... proteins in selected adjuvants

@nl

P1433

Q34302085-C7AE7622-2DBE-49B0-BC8E-13A4BF7FA7A2

P1476

Q34302085-5777B9F5-365A-48F0-9DCD-9B7CF53327A0

P2093

Q34302085-023E3198-3164-4160-8158-BF05B9402E53

Q34302085-0EE00A2B-9BA3-42F7-AA3B-1326DBFBC499

Q34302085-1C4EF65F-3EBF-404C-84BD-AFF95D8E2386

Q34302085-73E359B1-2EDC-49D5-8BFD-ED721751780C

Q34302085-AA1F380F-09A6-4C90-9AA4-02C59D2E45AD

Q34302085-FC934B6E-260E-425E-AEB9-03C36BDFF1AF

P2860

Q34302085-0706B2D8-089A-4EF2-A866-341A35A360B1

Q34302085-0791326F-3078-4E2C-8F62-F042861B3574

Q34302085-08E1F219-07F8-4CBD-A1BB-D7CDBB1FDB60

Q34302085-0AB5C4ED-28A2-4FAD-ACF8-F31924F67CD9

Q34302085-1A948A75-B1C3-468A-B971-6FB0A500CE8F

Q34302085-20DEF290-4AC7-4DAB-958E-B0834A65D588

Q34302085-22111ED5-3F58-482A-819B-1331EA0C410F

Q34302085-2B1076B4-60DF-4FEE-8E5D-AA6A0DE685D8

Q34302085-36C61D20-25E7-45E2-A478-8DA3F56F253F

Q34302085-3870BABF-3AF5-4CAB-9D54-730776A312AB

P304

Q34302085-5F21EC8A-3B28-41C5-89D3-F13687D34E03

P31

Q34302085-F29D17E3-D4A9-49A1-B0ED-C20DB6FFE97D

P356

Q34302085-59A3EEE6-CAB3-49F5-8EAF-C90D334071D1

P407

Q34302085-B74095D0-26C3-4D97-9FC3-106DB91BFD37

P433

Q34302085-3F764845-5CB2-4C9E-A2EB-9612E9F321BF

P478

Q34302085-DD9B8B74-3DEE-4635-81F8-B98B4E79259C

P577

Q34302085-0A2787AC-9A1A-4D8A-BE0B-786703F71841

P5875

Q34302085-18AB6312-F332-4A20-B523-4A36DD2688D5

P698

Q34302085-EAF637DC-3B85-46E5-91DA-DBA2125DD589

P921

Q34302085-D445ABEB-E454-4B0E-B229-5A999919D24B

P932

Q34302085-3B202CA0-F4DA-4000-BB66-C5137F25FF61

P356

JVI.80.3.1414-1426.2006

P1433

Journal of Virology

P1476

Characterization of antibody r ...... proteins in selected adjuvants

@en

P2093

G Voss

http://www.w3.org/2001/XMLSchema#string

J R Mascola

http://www.w3.org/2001/XMLSchema#string

K Svehla

http://www.w3.org/2001/XMLSchema#string

N L Mathy

http://www.w3.org/2001/XMLSchema#string

R Wyatt

http://www.w3.org/2001/XMLSchema#string

Y Li

http://www.w3.org/2001/XMLSchema#string

P2860

HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor

Identification of a major co-receptor for primary isolates of HIV-1

Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design

Core structure of gp41 from the HIV envelope glycoprotein

Atomic structure of the ectodomain from HIV-1 gp41

A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors

Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120.

The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus

The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates

Binding of HTLV-III/LAV to T4+ T cells by a complex of the 110K viral protein and the T4 molecule

P304

1414-1426

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.80.3.1414-1426.2006

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

80

http://www.w3.org/2001/XMLSchema#string

P577

2006-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7357375

http://www.w3.org/2001/XMLSchema#string

P698

16415019

http://www.w3.org/2001/XMLSchema#string

P921

P932

1346938

http://www.w3.org/2001/XMLSchema#string